A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
Lead Research Organisation:
Imperial College London
Department Name: Immunology and Inflammation
Abstract
There is a need for new therapies to reduce time to remission in patients suffering from ANCA associated Vasculitis treated with Rituximab. This projects mechanistically investigates the utility of targeting the Bcell survival factor B-Lys in combination with rituximab in reducing remission in the setting f ANCA associated Vasculitis
Technical Summary
Experimental medicine study to investigate the combination of belimumab and rituximab in man
Organisations
| Description | Imperial College Vasculitis Centre PPI Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Vasculitis Centre PPI events. Informational events for pateints and carers at Imperial College Vasculitis Centre, where we presented updates in current laboratory and clinical research projects undertaken at the Centre. Attended by 30 patients and 10 investigators. |
| Year(s) Of Engagement Activity | 2023 |